The basis for the adverse effects of approved drugs for treating patients with AD is the inhibition of cholinesterases in the basal ganglia, peripheral nervous system, and parasympathetic autonomic nervous system resulting in excess of acetylcholine24. The gene discussed is BCHE; the disease is Alzheimer disease.